Clinical Trials
180
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (178 trials with phase data)• Click on a phase to view related trials
Study Comparing Tapinarof Cream 1% to VTAMA ® (Tapinarof Cream 1%) in the Treatment of Plaque Psoriasis
- Conditions
- Plaque Type Psorisis
- Interventions
- First Posted Date
- 2024-12-19
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 560
- Registration Number
- NCT06742957
- Locations
- 🇺🇸
Site 12107, Scottsdale, Arizona, United States
🇺🇸Site 12101, Bryant, Arkansas, United States
🇺🇸Site 12110, Dublin, California, United States
Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 1050
- Registration Number
- NCT05617820
- Locations
- 🇺🇸
Site 10112, Birmingham, Alabama, United States
🇺🇸Site 10146, Chandler, Arizona, United States
🇺🇸Site 10103, Sacramento, California, United States
Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 807
- Registration Number
- NCT05550337
- Locations
- 🇺🇸
Site 10011, New Orleans, Louisiana, United States
🇺🇸Site 10001, Brandon, Florida, United States
🇺🇸Site 10003, Fort Lauderdale, Florida, United States
Study to Compare Efficacy and Safety of TEV-45779 With XOLAIR (Omalizumab) in Adults With Chronic Idiopathic Urticaria
- Conditions
- Chronic Urticaria
- First Posted Date
- 2021-07-26
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 608
- Registration Number
- NCT04976192
- Locations
- 🇺🇸
10008, Bakersfield, California, United States
🇺🇸Site 10001, Clearwater, Florida, United States
🇺🇸10012, Coral Gables, Florida, United States
A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis
- Conditions
- Osteoporosis, Postmenopausal
- First Posted Date
- 2021-01-28
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 332
- Registration Number
- NCT04729621
- Locations
- 🇺🇸
Teva Site 103, Phoenix, Arizona, United States
🇺🇸Teva Site 119, Tucson, Arizona, United States
🇺🇸Teva Site 118, San Diego, California, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 36
- Next